Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know
This month, the world should get the first results from a clinical trial testing the…
Category: Business
STAT Plus: Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer
Immunomedics is stopping a Phase 3 clinical trial due to “compelling evidence of efficacy” demonstrated…
STAT Plus: Boston Scientific cutting hours and pay as revenue drops
Boston Scientific said Thursday that it’s cutting wages for many of its roughly 36,000 global…
STAT Plus: The biotech scorecard for the second quarter: 18 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the second…
Amarin loses legal fight over heart drug patent; shares sink
Amarin shares fell sharply Monday evening after a federal judge ruled that key patents covering…
‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19
The CEO of a global pharmaceutical company’s operations in Italy has advice for anyone expecting…
STAT Plus: Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval
After meeting with the Food and Drug Administration, Sage Therapeutics said Wednesday that it will…
Drug makers grounding salespeople as coronavirus impact on business spreads
In another sign that the coronavirus pandemic is fundamentally interrupting the way biopharma conducts business,…
How one company made $208 million on an untested coronavirus vaccine
Inovio Pharmaceuticals (INO), a drug company that has existed for four decades without developing an…
STAT Plus: The Engine at MIT is revving up the potential of ‘tough tech’
If you happen to bump into Bill Gates or Tim Cook in Central Square in…
STAT Plus: Thermo Fisher buys Dutch diagnostics company for $11.5 billion
Thermo Fisher Scientific (TMO) is buying the Dutch diagnostics company Qiagen (QGEN) in an $11.5…
STAT Plus: CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven
Gilead’s board hired CEO Dan O’Day a year ago to look for new areas of…
Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease
The drug maker Biogen announced late Thursday that it would license two preclinical drugs from…
STAT Plus: With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption
Months and even years after a successful bone marrow transplant, when patients in remission finally…
STAT Plus: Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison
The founder of a biotech who said his company had developed a painkiller that would…
Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk
The Japanese drug maker Eisai on Thursday said it would withdraw the weight-loss drug Belviq…
Opinion: STAT Plus: Why medtech is a different beast than biotech in the life sciences pack
Biotech innovations dominate the life science news cycle — think CRISPR for gene editing or…
STAT Plus: With new combination drug data, Exelixis takes another shot at prostate cancer treatment
In 2014, the Bay Area biotech company Exelixis (EXEL) tried to develop a drug for…
STAT Plus: Investor impatience with Gilead reclamation project sparks acquisition chatter
In recent days, there’s been investor chatter about stalled-out Gilead Sciences (GILD) becoming a takeover…
STAT Plus: Beam Therapeutics raises $180 million in IPO
Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public…
STAT Plus: Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so
Move aside, Big Tech. If 2017 was the year technology giants like Apple set their…
Biogen wins patent challenge to key multiple sclerosis drug
A U.S. appeals panel on Wednesday denied a patent challenge against Biogen’s multiple sclerosis drug…
Merck to spin off new $6.5 billion firm focused on women’s health, older drugs
Merck said Wednesday that it will create a new drug company to sell many of…
STAT Plus: This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund
Marc Andreessen, famous for proclaiming that software was “eating the world,” said in 2009 that…
.jpg)
STAT Plus: FDA approves the first treatment for peanut allergy, but commercial success is hardly assured
Children and teenagers with severe, sometimes life-threatening peanut allergies can reduce their risk from accidental…
STAT Plus: European regulators could take a harder line on the review of an Agios blood cancer drug
A European regulatory setback for a Bristol-Myers Squibb (BMY) blood-cancer drug could have a negative…
STAT Plus: As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking
There are few things in this world more squishy than Wonder Bread. Exception: Biogen’s answers…
STAT Plus: Spring Bank scraps hepatitis R&D after patient dies in trial
Spring Bank Pharmaceuticals (SBPH) said Wednesday it was abandoning efforts to develop a drug to…
Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter
Zolgensma, the Novartis gene therapy for infants and the world’s most expensive medicine, continues to…
Three star scientists announce plan to solve biotech’s ‘missing women’ problem
They are the biotech equivalent of the “missing girls” in countries with a skewed gender…
STAT Plus: Prosecutors identified ‘Pharma Co. X’ as central to alleged opioid kickback scheme. Was it Purdue?
Federal prosecutors this week announced a $145 million settlement with an electronic health records company…
STAT Plus: Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks
Biotech earnings season kicks off Thursday with fourth-quarter reports from Alexion Pharma (ALXN), Amgen (AMGN),…
STAT Plus: Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial
Acceleron Pharma said Monday that a mid-stage clinical trial involving an experimental drug for pulmonary…
STAT Plus: The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: serendipity
You know Kendall Square’s office rents have gotten stratospheric when a CEO compares the neighborhood…
STAT Plus: Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme
The founder of Insys Therapeutics was sentenced to 5½ years in federal prison Thursday for…
23andMe laying off 14% of employees amid slump in DNA spit kit sales
In the latest sign of a slump in consumer genetic testing, 23andMe is laying off…
STAT Plus: Former Insys executive who dressed as giant fentanyl bottle gets 26-month sentence
A former high-ranking Insys Therapeutics executive who dressed as a giant fentanyl spray bottle in…
STAT Plus: Former Insys executive sentenced to a year and a day for her role in opioid bribery scheme
A former pharmaceutical executive and one-time stripper was sentenced to a year and a day…
STAT Plus: How swallowing a star might keep you from missing a dose of medicine
SAN FRANCISCO — Plenty of drug industry executives who take over this city for a…
STAT Plus: ‘We have a tragedy of the commons’: How a VC thinks his new company can lower drug prices
A venture capitalist made some waves early in the J.P. Morgan Healthcare Conference when he…
A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down
The U.S. health system could get some relief from rising drug prices from an unlikely…
STAT Plus: Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline
Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for…
STAT Plus: Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer
Blueprint Medicines won approval Thursday of its first drug, a precision medicine that dramatically shrank…
At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find
In 2016, the biotech billionaire Dr. Patrick Soon-Shiong set himself a deadline: By 2020, he…
3 trends in biotech to watch in 2020
For biotech, 2019 ended like the penultimate episode of a prestige TV show. We got…
STAT Plus: Sarepta sells international rights to Duchenne gene therapy to Roche
Sarepta Therapeutics said Monday that it will receive $1.15 billion in cash and an equity…
The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’
The Federal Trade Commission is challenging DNA sequencing giant Illumina’s proposed $1.2 billion purchase of…
Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying
WASHINGTON — Purdue Pharma, the embattled opioid maker, has quietly split ways with PhRMA, the…
STAT Plus: Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation
Bankrupt microbiome-testing startup uBiome, once valued at $600 million by Silicon Valley investors, preliminarily sold…
STAT Plus: In tight Massachusetts job market, it’s relo for biotech and remote for tech hires
A state unemployment rate of 2.9% doesn’t quite capture how tight the job market is…